RARE
Ultragenyx Pharmaceutical Inc.
$56.26
Earnings Summary
Revenue | $147.03Mn |
Net Profits | $-131.6Mn |
Net Profit Margins | -89.51% |
Highlights
Ultragenyx Pharmaceutical Inc.’s revenue jumped 35.75% since last year same period to $147.03Mn in the Q2 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 35.09% jump in its revenue since last 3-months.
Ultragenyx Pharmaceutical Inc.’s net profit jumped 17.66% since last year same period to $-131.6Mn in the Q2 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 22.9% jump in its net profits since last 3-months.
Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 39.34% since last year same period to -89.51% in the Q2 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 42.93% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Ultragenyx Pharmaceutical Inc. post its latest quarter earnings
EPS Estimate Current Year | -1.75 |
Highlights
Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.75.
Key Ratios
Key ratios of the Ultragenyx Pharmaceutical Inc. post its Q2 2024 earnings
Earning Per Share (EPS) | -1.52 |
Highlights
Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 32.44% since last year same period to -1.52 in the Q2 2024. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 32.44% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-03 | -1.73 | -2.03 | -17.34% |
2024-08-02 | -1.69 | -1.52 | 10.06% |
₹0 US Stocks a/c Opening Fee